Prognostic value, localization and correlation of PD-1/PD-L1, CD8 and FOXP3 with the desmoplastic stroma in pancreatic ductal adenocarcinoma

被引:72
|
作者
Diana, Angela [1 ]
Wang, Lai Mun [2 ]
D'Costa, Zenobia [1 ]
Allen, Paul [2 ]
Azad, Abul [1 ]
Silva, Michael A. [3 ]
Soonawalla, Zahir [3 ]
Liu, Stanley [4 ]
McKenna, W. Gillies [1 ]
Muschel, Ruth J. [1 ]
Fokas, Emmanouil [1 ]
机构
[1] Univ Oxford, CRUK MRC Oxford Inst Radiat Oncol, Dept Oncol, Oxford, England
[2] Oxford Univ Hosp NHS Fdn Trust, Dept Pathol, Oxford, England
[3] Oxford Univ Hosp NHS Fdn Trust, Dept Surg, Oxford, England
[4] Univ Toronto, Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Dept Radiat Oncol, Toronto, ON, Canada
关键词
PD-1/PD-L1; CD8; immune; prognosis; pancreatic cancer; Immunology and Microbiology Section; Immune response; Immunity; IMMUNE CHECKPOINT BLOCKADE; T-CELL INFILTRATION; COLORECTAL-CANCER; FLUID SECRETION; NECK-CANCER; TUMOR; THERAPY; IMMUNOTHERAPY; RAT; MICROENVIRONMENT;
D O I
10.18632/oncotarget.10038
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We examined the prognostic value of programmed cell death-1 (PD-1) and its ligand (PD-L1) together with CD8+ tumor-infiltrating lymphocytes (TILs) and FOXP3+ Tregs in resectable pancreatic ductal adenocarcinoma (PDAC) samples treated with adjuvant chemotherapy. Whole-mount FFPE tissue sections from 145 pancreatectomies were immunohistochemically stained for PD-1, PD-L1, CD8 and FOXP3. Their expression was correlated with clinicopathological characteristics, and overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastases free-survival (DMFS), in the context of stroma density (haematoxylin-eosin) and activity (alpha-smooth muscle actin) and in regard to intratumoral lymphoid aggregates. The median OS was 21 months after a mean follow-up of 20 months (range, 2-69 months). In multivariate analysis, high PD-1+ TILs expression was associated with better OS (p = 0.049), LPFS (p = 0.017) and DMFS (p = 0.021). Similar findings were observed for CD8+ TILs, whereas FOXP3 and PD-L1 lacked prognostic significance. Although TIL distribution was heterogeneous, tumors of high stroma density had higher infiltration of CD8+ TILs than loose density stroma and vice versa (p < 0.001), whereas no correlation was found with stromal activity. Sixty (41.4%) tumors contained lymphoid aggregates and the presence of PD-1+ TILs was associated with better OS (p = 0.030), LPFS (p = 0.025) and DMFS (p = 0.033), whereas CD8+ TILs only correlated with superior LPFS (p = 0.039). PD-1+ and CD8+ TILs constitute independent prognostic markers in patients with PDAC treated with adjuvant chemotherapy. Our study provides important insight on the role of PD-1/PD-L1 in the context of desmoplastic stroma and could help guide future immunotherapies in PDAC.
引用
收藏
页码:40992 / 41004
页数:13
相关论文
共 50 条
  • [31] Tumor necrosis correlates with PD-L1 and PD-1 expression in lung adenocarcinoma
    Reiniger, Lilla
    Teglasi, Vanda
    Pipek, Orsolya
    Rojko, Livia
    Glasz, Tibor
    Vagvoelgyi, Attila
    Kovalszky, Ilona
    Gyulai, Marton
    Lohinai, Zoltan
    Raso, Erzsebet
    Timar, Jozsef
    Dome, Balazs
    Szallasi, Zoltan
    Moldvay, Judit
    ACTA ONCOLOGICA, 2019, 58 (08) : 1087 - 1094
  • [32] Prognostic role and correlation of CA9, CD31, CD68 and CD20 with the desmoplastic stroma in pancreatic ductal adenocarcinoma
    Diana, Angela
    Wang, Lai Mun
    D'Costa, Zenobia
    Azad, Abul
    Silva, Michael A.
    Soonawalla, Zahir
    Allen, Paul
    Liu, Stanley
    McKenna, W. Gillies
    Muschel, Ruth J.
    Fokas, Emmanouil
    ONCOTARGET, 2016, 7 (45) : 72819 - 72832
  • [33] PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
    Hsiang-Ling Ho
    Teh-Ying Chou
    Shung-Haur Yang
    Jeng-Kai Jiang
    Wei-Shone Chen
    Yee Chao
    Hao-Wei Teng
    Journal of Cancer Research and Clinical Oncology, 2019, 145 : 1785 - 1794
  • [34] Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
    S. Mazher Hussain
    Rita G. Kansal
    Marcus A. Alvarez
    T. J. Hollingsworth
    Abul Elahi
    Gustavo Miranda-Carboni
    Leah E. Hendrick
    Ajeeth K. Pingili
    Lorraine M. Albritton
    Paxton V. Dickson
    Jeremiah L. Deneve
    Danny Yakoub
    D. Neil Hayes
    Michio Kurosu
    David Shibata
    Liza Makowski
    Evan S. Glazer
    Cellular Oncology, 2021, 44 : 673 - 687
  • [35] Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression
    Hussain, S. Mazher
    Kansal, Rita G.
    Alvarez, Marcus A.
    Hollingsworth, T. J.
    Elahi, Abul
    Miranda-Carboni, Gustavo
    Hendrick, Leah E.
    Pingili, Ajeeth K.
    Albritton, Lorraine M.
    Dickson, Paxton, V
    Deneve, Jeremiah L.
    Yakoub, Danny
    Hayes, D. Neil
    Kurosu, Michio
    Shibata, David
    Makowski, Liza
    Glazer, Evan S.
    CELLULAR ONCOLOGY, 2021, 44 (03) : 673 - 687
  • [36] PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC
    Wang, Xiuchao
    Li, Xin
    Wei, Xunbin
    Jiang, Haiping
    Lan, Chungen
    Yang, Shengyu
    Wang, Han
    Yang, Yanhui
    Tian, Caijuan
    Xu, Zanmei
    Zhang, Jiangyan
    Hao, Jihui
    Ren, He
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2020, 5 (01)
  • [37] PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1
    Ho, Hsiang-Ling
    Chou, Teh-Ying
    Yang, Shung-Haur
    Jiang, Jeng-Kai
    Chen, Wei-Shone
    Chao, Yee
    Teng, Hao-Wei
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (07) : 1785 - 1794
  • [38] Combination PD-1 and PD-L1 Blockade Promotes Durable Neoantigen-Specific T Cell-Mediated Immunity in Pancreatic Ductal Adenocarcinoma
    Burrack, Adam L.
    Spartzt, Ellen J.
    Raynort, Jackson F.
    Wang, Iris
    Olson, Margaret
    Stromnes, Ingunn M.
    CELL REPORTS, 2019, 28 (08): : 2140 - +
  • [39] The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis
    Xu, Gang
    Sun, Lejia
    Li, Yunzhu
    Xie, Feihu
    Zhou, Xiaoxiang
    Yang, Huayu
    Du, Shunda
    Xu, Haifeng
    Mao, Yilei
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [40] Restored CD8+PD-1+ T Cells Facilitate the Response to Anti-PD-1 for Patients With Pancreatic Ductal Adenocarcinoma
    Zhu, Qian
    Qiao, Guoliang
    Huang, Lefu
    Xu, Chang
    Guo, Deliang
    Wang, Shuo
    Zhao, Jing
    Song, Yuguang
    Liu, Bing
    Chen, Zheng
    Yang, Zhiyong
    Yuan, Yufeng
    FRONTIERS IN ONCOLOGY, 2022, 12